ApprovedFDA approval

Awiqli (insulin icodec-abae)

Novo Nordisk (NVO)

Marketer take

The first of two once-weekly basal insulins approved in 2026, giving insulin marketers a new dosing-frequency message in primary care; Lilly's weekly Onswik followed in September.

Sponsor company
Novo Nordisk (NVO)
Indication
To improve glycemic control in adults with type 2 diabetes mellitus
Therapeutic area
Diabetes, Metabolic
Event
FDA approval
Date
Mar 26, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move